 Plasma Fractionation Market Insights, Competitive Landscape, and Market Forecast - 2033
The global plasma fractionation market is on a steady growth trajectory, supported by the rising demand for plasma-derived therapeutics and expanding clinical applications across multiple disease a... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global plasma fractionation market is on a steady growth trajectory, supported by the rising demand for plasma-derived therapeutics and expanding clinical applications across multiple disease areas. The market is expected to reach US$ 34.4 billion in 2026 and is projected to grow further to US$ 57.3 billion by 2033, registering a CAGR of 7.50% during the forecast period. Plasma fractionation is a sophisticated biopharmaceutical process that separates plasma proteins such as immunoglobulins, albumin, and clotting factors from human blood. These proteins are essential in managing life-threatening conditions including immune disorders, hemophilia, neurological diseases, and trauma-related complications. Increasing reliance on biologics and specialized therapies is strengthening the role of plasma-derived products in modern healthcare systems worldwide.Market Insights The plasma fractionation market is experiencing dynamic transformation due to advancements in fractionation technologies and rising clinical acceptance of plasma-derived therapies. Immunoglobulins dominate the market owing to their extensive use in treating autoimmune and immunodeficiency disorders. Albumin remains another critical segment, widely utilized in surgeries, trauma care, and liver-related conditions. Growing awareness regarding the therapeutic benefits of plasma proteins is driving demand, particularly in developed healthcare markets. At the same time, improvements in plasma collection processes and expansion of donation centers are enhancing supply capabilities. Regulatory authorities across regions are reinforcing stringent quality and safety standards, ensuring product efficacy and boosting patient confidence. Continuous research efforts are also enabling innovation in plasma-based therapies, contributing to long-term market expansion. Drivers The growth of the plasma fractionation market is primarily driven by the increasing prevalence of chronic and rare diseases. Conditions such as hemophilia, primary immunodeficiency disorders, and neurological ailments are creating sustained demand for plasma-derived therapies. The global aging population further amplifies this demand, as older individuals are more prone to complex health conditions requiring advanced treatments. Technological progress in plasma processing and purification techniques has improved production efficiency and scalability. In addition, the rapid expansion of plasma collection centers, especially in North America and parts of Europe, has significantly increased plasma availability. Favorable reimbursement policies and rising healthcare spending are also encouraging the adoption of plasma-based therapeutics, despite their relatively high cost. Business Opportunity The plasma fractionation market offers considerable opportunities for growth and innovation. Emerging economies, particularly in Asia Pacific and Latin America, are becoming key focus areas due to increasing healthcare investments and expanding access to advanced medical treatments. Market players are actively investing in capacity expansion and strategic collaborations to strengthen their competitive position. Opportunities are also emerging in the development of next-generation plasma-derived therapies and recombinant alternatives that enhance treatment outcomes. The growing trend toward personalized medicine is further encouraging the customization of plasma-based products. Moreover, digital tools and data-driven strategies are being utilized to improve donor engagement and optimize plasma collection efficiency. As global demand continues to rise, companies that prioritize innovation and supply chain expansion are likely to gain a competitive edge. Region Analysis North America holds the largest share in the global plasma fractionation market, supported by its advanced healthcare infrastructure, strong plasma collection network, and presence of leading industry players. The United States leads the region due to its large donor base and favorable regulatory environment. Europe represents another significant market, with countries such as Germany, France, and the United Kingdom demonstrating high adoption of plasma-derived therapies. The region benefits from well-established healthcare systems and increasing focus on rare disease management. Asia Pacific is emerging as the fastest-growing region, driven by rising healthcare awareness, growing patient population, and improving diagnostic capabilities in countries like China, India, and Japan. Meanwhile, Latin America and the Middle East and Africa are gradually expanding, supported by ongoing improvements in healthcare infrastructure and access to advanced therapies. Key Players • CSL Limited • Takeda Pharmaceutical Company • Sanquin • Biotest AG • GRIFOLS • Baxter International Inc. • Kedrion • Octapharma AG • Taibang Biological Group Co., Ltd Segmentation By Product • Immunoglobulins o Intravenous Immunoglobulins o Subcutaneous Immunoglobulins o Other Immunoglobulins • Coagulation Factor Concentrates o Factor VIII o Factor IX o Von Willebrand Factor o Prothrombin Complex Concentrate o Fibrinogen Concentrates o Factor XIII o Other Coagulation Factor Concentrates • Albumin • Protease Inhibitors • Other Plasma Products By Application • Neurology • Immunology • Haematology • Critical care • Pulmonology • Haemato-Oncology • Rheumatology • Other Applications By End User • Hospitals and Clinics • Clinical Research Laboratories • Academic institutes By Region • North America • Europe • Asia Pacific • Latin America • Middle East and Africa Table of Contents1. Executive Summary1.1. Global Plasma Fractionation Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Plasma Fractionation Market Outlook, 2020-2033 3.1. Global Plasma Fractionation Market Outlook, by Product, Value (US$ Bn), 2020-2033 3.1.1. Immunoglobulins 3.1.1.1. Intravenous Immunoglobulins 3.1.1.2. Subcutaneous Immunoglobulins 3.1.1.3. Other Immunoglobulins 3.1.2. Coagulation Factor Concentrates 3.1.2.1. Factor VIII 3.1.2.2. Factor IX 3.1.2.3. Von Willebrand Factor 3.1.2.4. Prothrombin Complex Concentrate 3.1.2.5. Fibrinogen Concentrates 3.1.2.6. Factor XIII 3.1.3. Albumin 3.1.4. Protease Inhibitors 3.1.5. Protease Inhibitors 3.2. Global Plasma Fractionation Market Outlook, by Application, Value (US$ Bn), 2020-2033 3.2.1. Neurology 3.2.2. Immunology 3.2.3. Haematology 3.2.4. Critical care 3.2.5. Pulmonology 3.2.6. Haemato-Oncology 3.2.7. Rheumatology 3.2.8. Other Applications 3.3. Global Plasma Fractionation Market Outlook, by End User, Value (US$ Bn), 2020-2033 3.3.1. Hospitals and Clinics 3.3.2. Clinical Research Laboratories 3.3.3. Academic institutes 3.4. Global Plasma Fractionation Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Plasma Fractionation Market Outlook, 2020-2033 4.1. North America Plasma Fractionation Market Outlook, by Product, Value (US$ Bn), 2020-2033 4.1.1. Immunoglobulins 4.1.1.1. Intravenous Immunoglobulins 4.1.1.2. Subcutaneous Immunoglobulins 4.1.1.3. Other Immunoglobulins 4.1.2. Coagulation Factor Concentrates 4.1.2.1. Factor VIII 4.1.2.2. Factor IX 4.1.2.3. Von Willebrand Factor 4.1.2.4. Prothrombin Complex Concentrate 4.1.2.5. Fibrinogen Concentrates 4.1.2.6. Factor XIII 4.1.3. Albumin 4.1.4. Protease Inhibitors 4.1.5. Protease Inhibitors 4.2. North America Plasma Fractionation Market Outlook, by Application, Value (US$ Bn), 2020-2033 4.2.1. Neurology 4.2.2. Immunology 4.2.3. Haematology 4.2.4. Critical care 4.2.5. Pulmonology 4.2.6. Haemato-Oncology 4.2.7. Rheumatology 4.2.8. Other Applications 4.3. North America Plasma Fractionation Market Outlook, by End User, Value (US$ Bn), 2020-2033 4.3.1. Hospitals and Clinics 4.3.2. Clinical Research Laboratories 4.3.3. Academic institutes 4.4. North America Plasma Fractionation Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Plasma Fractionation Market Outlook, by Product, 2020-2033 4.4.2. U.S. Plasma Fractionation Market Outlook, by Application, 2020-2033 4.4.3. U.S. Plasma Fractionation Market Outlook, by End User, 2020-2033 4.4.4. Canada Plasma Fractionation Market Outlook, by Product, 2020-2033 4.4.5. Canada Plasma Fractionation Market Outlook, by Application, 2020-2033 4.4.6. Canada Plasma Fractionation Market Outlook, by End User, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Plasma Fractionation Market Outlook, 2020-2033 5.1. Europe Plasma Fractionation Market Outlook, by Product, Value (US$ Bn), 2020-2033 5.1.1. Immunoglobulins 5.1.1.1. Intravenous Immunoglobulins 5.1.1.2. Subcutaneous Immunoglobulins 5.1.1.3. Other Immunoglobulins 5.1.2. Coagulation Factor Concentrates 5.1.2.1. Factor VIII 5.1.2.2. Factor IX 5.1.2.3. Von Willebrand Factor 5.1.2.4. Prothrombin Complex Concentrate 5.1.2.5. Fibrinogen Concentrates 5.1.2.6. Factor XIII 5.1.3. Albumin 5.1.4. Protease Inhibitors 5.1.5. Protease Inhibitors 5.2. Europe Plasma Fractionation Market Outlook, by Application, Value (US$ Bn), 2020-2033 5.2.1. Neurology 5.2.2. Immunology 5.2.3. Haematology 5.2.4. Critical care 5.2.5. Pulmonology 5.2.6. Haemato-Oncology 5.2.7. Rheumatology 5.2.8. Other Applications 5.3. Europe Plasma Fractionation Market Outlook, by End User, Value (US$ Bn), 2020-2033 5.3.1. Hospitals and Clinics 5.3.2. Clinical Research Laboratories 5.3.3. Academic institutes 5.4. Europe Plasma Fractionation Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.2. Germany Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.3. Germany Plasma Fractionation Market Outlook, by End User, 2020-2033 5.4.4. Italy Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.5. Italy Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.6. Italy Plasma Fractionation Market Outlook, by End User, 2020-2033 5.4.7. France Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.8. France Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.9. France Plasma Fractionation Market Outlook, by End User, 2020-2033 5.4.10. U.K. Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.11. U.K. Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.12. U.K. Plasma Fractionation Market Outlook, by End User, 2020-2033 5.4.13. Spain Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.14. Spain Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.15. Spain Plasma Fractionation Market Outlook, by End User, 2020-2033 5.4.16. Russia Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.17. Russia Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.18. Russia Plasma Fractionation Market Outlook, by End User, 2020-2033 5.4.19. Rest of Europe Plasma Fractionation Market Outlook, by Product, 2020-2033 5.4.20. Rest of Europe Plasma Fractionation Market Outlook, by Application, 2020-2033 5.4.21. Rest of Europe Plasma Fractionation Market Outlook, by End User, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Plasma Fractionation Market Outlook, 2020-2033 6.1. Asia Pacific Plasma Fractionation Market Outlook, by Product, Value (US$ Bn), 2020-2033 6.1.1. Immunoglobulins 6.1.1.1. Intravenous Immunoglobulins 6.1.1.2. Subcutaneous Immunoglobulins 6.1.1.3. Other Immunoglobulins 6.1.2. Coagulation Factor Concentrates 6.1.2.1. Factor VIII 6.1.2.2. Factor IX 6.1.2.3. Von Willebrand Factor 6.1.2.4. Prothrombin Complex Concentrate 6.1.2.5. Fibrinogen Concentrates 6.1.2.6. Factor XIII 6.1.3. Albumin 6.1.4. Protease Inhibitors 6.1.5. Protease Inhibitors 6.2. Asia Pacific Plasma Fractionation Market Outlook, by Application, Value (US$ Bn), 2020-2033 6.2.1. Neurology 6.2.2. Immunology 6.2.3. Haematology 6.2.4. Critical care 6.2.5. Pulmonology 6.2.6. Haemato-Oncology 6.2.7. Rheumatology 6.2.8. Other Applications 6.3. Asia Pacific Plasma Fractionation Market Outlook, by End User, Value (US$ Bn), 2020-2033 6.3.1. Hospitals and Clinics 6.3.2. Clinical Research Laboratories 6.3.3. Academic institutes 6.4. Asia Pacific Plasma Fractionation Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Plasma Fractionation Market Outlook, by Product, 2020-2033 6.4.2. China Plasma Fractionation Market Outlook, by Application, 2020-2033 6.4.3. China Plasma Fractionation Market Outlook, by End User, 2020-2033 6.4.4. Japan Plasma Fractionation Market Outlook, by Product, 2020-2033 6.4.5. Japan Plasma Fractionation Market Outlook, by Application, 2020-2033 6.4.6. Japan Plasma Fractionation Market Outlook, by End User, 2020-2033 6.4.7. South Korea Plasma Fractionation Market Outlook, by Product, 2020-2033 6.4.8. South Korea Plasma Fractionation Market Outlook, by Application, 2020-2033 6.4.9. South Korea Plasma Fractionation Market Outlook, by End User, 2020-2033 6.4.10. India Plasma Fractionation Market Outlook, by Product, 2020-2033 6.4.11. India Plasma Fractionation Market Outlook, by Application, 2020-2033 6.4.12. India Plasma Fractionation Market Outlook, by End User, 2020-2033 6.4.13. Southeast Asia Plasma Fractionation Market Outlook, by Product, 2020-2033 6.4.14. Southeast Asia Plasma Fractionation Market Outlook, by Application, 2020-2033 6.4.15. Southeast Asia Plasma Fractionation Market Outlook, by End User, 2020-2033 6.4.16. Rest of SAO Plasma Fractionation Market Outlook, by Product, 2020-2033 6.4.17. Rest of SAO Plasma Fractionation Market Outlook, by Application, 2020-2033 6.4.18. Rest of SAO Plasma Fractionation Market Outlook, by End User, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Plasma Fractionation Market Outlook, 2020-2033 7.1. Latin America Plasma Fractionation Market Outlook, by Product, Value (US$ Bn), 2020-2033 7.1.1. Immunoglobulins 7.1.1.1. Intravenous Immunoglobulins 7.1.1.2. Subcutaneous Immunoglobulins 7.1.1.3. Other Immunoglobulins 7.1.2. Coagulation Factor Concentrates 7.1.2.1. Factor VIII 7.1.2.2. Factor IX 7.1.2.3. Von Willebrand Factor 7.1.2.4. Prothrombin Complex Concentrate 7.1.2.5. Fibrinogen Concentrates 7.1.2.6. Factor XIII 7.1.3. Albumin 7.1.4. Protease Inhibitors 7.1.5. Protease Inhibitors 7.2. Latin America Plasma Fractionation Market Outlook, by Application, Value (US$ Bn), 2020-2033 7.2.1. Neurology 7.2.2. Immunology 7.2.3. Haematology 7.2.4. Critical care 7.2.5. Pulmonology 7.2.6. Haemato-Oncology 7.2.7. Rheumatology 7.2.8. Other Applications 7.3. Latin America Plasma Fractionation Market Outlook, by End User, Value (US$ Bn), 2020-2033 7.3.1. Hospitals and Clinics 7.3.2. Clinical Research Laboratories 7.3.3. Academic institutes 7.4. Latin America Plasma Fractionation Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Plasma Fractionation Market Outlook, by Product, 2020-2033 7.4.2. Brazil Plasma Fractionation Market Outlook, by Application, 2020-2033 7.4.3. Brazil Plasma Fractionation Market Outlook, by End User, 2020-2033 7.4.4. Mexico Plasma Fractionation Market Outlook, by Product, 2020-2033 7.4.5. Mexico Plasma Fractionation Market Outlook, by Application, 2020-2033 7.4.6. Mexico Plasma Fractionation Market Outlook, by End User, 2020-2033 7.4.7. Argentina Plasma Fractionation Market Outlook, by Product, 2020-2033 7.4.8. Argentina Plasma Fractionation Market Outlook, by Application, 2020-2033 7.4.9. Argentina Plasma Fractionation Market Outlook, by End User, 2020-2033 7.4.10. Rest of LATAM Plasma Fractionation Market Outlook, by Product, 2020-2033 7.4.11. Rest of LATAM Plasma Fractionation Market Outlook, by Application, 2020-2033 7.4.12. Rest of LATAM Plasma Fractionation Market Outlook, by End User, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Plasma Fractionation Market Outlook, 2020-2033 8.1. Middle East & Africa Plasma Fractionation Market Outlook, by Product, Value (US$ Bn), 2020-2033 8.1.1. Immunoglobulins 8.1.1.1. Intravenous Immunoglobulins 8.1.1.2. Subcutaneous Immunoglobulins 8.1.1.3. Other Immunoglobulins 8.1.2. Coagulation Factor Concentrates 8.1.2.1. Factor VIII 8.1.2.2. Factor IX 8.1.2.3. Von Willebrand Factor 8.1.2.4. Prothrombin Complex Concentrate 8.1.2.5. Fibrinogen Concentrates 8.1.2.6. Factor XIII 8.1.3. Albumin 8.1.4. Protease Inhibitors 8.1.5. Protease Inhibitors 8.2. Middle East & Africa Plasma Fractionation Market Outlook, by Application, Value (US$ Bn), 2020-2033 8.2.1. Neurology 8.2.2. Immunology 8.2.3. Haematology 8.2.4. Critical care 8.2.5. Pulmonology 8.2.6. Haemato-Oncology 8.2.7. Rheumatology 8.2.8. Other Applications 8.3. Middle East & Africa Plasma Fractionation Market Outlook, by End User, Value (US$ Bn), 2020-2033 8.3.1. Hospitals and Clinics 8.3.2. Clinical Research Laboratories 8.3.3. Academic institutes 8.4. Middle East & Africa Plasma Fractionation Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Plasma Fractionation Market Outlook, by Product, 2020-2033 8.4.2. GCC Plasma Fractionation Market Outlook, by Application, 2020-2033 8.4.3. GCC Plasma Fractionation Market Outlook, by End User, 2020-2033 8.4.4. South Africa Plasma Fractionation Market Outlook, by Product, 2020-2033 8.4.5. South Africa Plasma Fractionation Market Outlook, by Application, 2020-2033 8.4.6. South Africa Plasma Fractionation Market Outlook, by End User, 2020-2033 8.4.7. Egypt Plasma Fractionation Market Outlook, by Product, 2020-2033 8.4.8. Egypt Plasma Fractionation Market Outlook, by Application, 2020-2033 8.4.9. Egypt Plasma Fractionation Market Outlook, by End User, 2020-2033 8.4.10. Nigeria Plasma Fractionation Market Outlook, by Product, 2020-2033 8.4.11. Nigeria Plasma Fractionation Market Outlook, by Application, 2020-2033 8.4.12. Nigeria Plasma Fractionation Market Outlook, by End User, 2020-2033 8.4.13. Rest of Middle East Plasma Fractionation Market Outlook, by Product, 2020-2033 8.4.14. Rest of Middle East Plasma Fractionation Market Outlook, by Application, 2020-2033 8.4.15. Rest of Middle East Plasma Fractionation Market Outlook, by End User, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. CSL Limited 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Takeda Pharmaceutical Company 9.4.3. Sanquin 9.4.4. Biotest AG 9.4.5. GRIFOLS 9.4.6. Baxter International Inc. 9.4.7. Kedrion 9.4.8. Octapharma AG 9.4.9. Taibang Biological Group Co., Ltd 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（plasma）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
